Processa Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
FY EPS (est.)
-$0.92next fiscal year
Monitoring Framework
Key Performance Indicators
Phase 2 NGC-Cap Breast Cancer Study Patient Enrollment Quarterly20.0Target: 20 (Enrollment completed for formal interim analysis)
Digital Asset Treasury Holdings (Chiliz - CHZ) Quarterly1.4MTarget: Maintain or expand digital asset treasury to diversify capital base
Quarterly Net Loss (USD) Quarterly3.4MTarget: Manage cash burn through disciplined spending
Watch Items
- Interim analysis of Phase 2 NGC-Cap trial in advanced or metastatic breast cancerTrigger: Release of safety and efficacy data comparing NGC-Cap to capecitabine monotherapyAction: Evaluate therapeutic index improvement (increased cancer-killing metabolite exposure without increased side effects) to determine Phase 3 trial design
- Nasdaq Minimum Bid Price Requirement ComplianceTrigger: Closing bid price below $1.00 per shareAction: Monitor stock price during grace periods; implement a reverse stock split if necessary to maintain Nasdaq listing
- Monetization of non-oncology assets (PCS12852 and PCS499)Trigger: Execution of out-licensing agreements or strategic partnershipsAction: Secure non-dilutive funding to extend cash runway and support oncology pipeline development
Research as of 20 Jun 2026